Poster presentations: Poster Viewing Session III: CLINICAL
Longitudinal optic coherence tomography imaging shows hyperreflective foci in RRMS
Jette Frederiksen
11
Defining Smo[u]ldering Associated Worsening (SAW) in MS: The SAW index study
Jeremy Hobart
95
SymptoMScreen questionnaire: a suitable outcome measure for MS clinical trials?
Jeremy Hobart
96
EDSS: confirming requirements, advancing interpretations, exposing novel insights
Jeremy Hobart
97
Ocrelizumab slows the rate of change of EDSS-measured progression in relapsing MS
Jeremy Hobart
98
COMPARISON OF OCRELIZUMAB CONCENTRATION AND AUTO ANTIBODIES BETWEEN TEST FACILITIES
Birgit Jensen
71
Pain in NMOSD and MOGAD: Prevalence, Predictors, and Impact on Quality of Life
Emine Koc
53
Long-Term Outcomes in Female Participants of the Ozanimod Open-Label Extension
Eva Kubala Havrdova
84
Long-Term Outcomes in Female Participants of the Ozanimod Open-Label Extension
Eva Kubala Havrdova
84
Interim results from the SATYSFACTION study, Patient Satisfaction with Tysabri SC
Yves Martinet
76
SDMT and Safety Outcomes at 1 Year in the ENLIGHTEN Study of Ozanimod in Early RMS
Robert Naismith
88
Long-term ozanimod safety in the DAYBREAK open-label extension trial
Krzysztof Selmaj
89